Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of parkinson disease

Journal of Neuropathology and Experimental Neurology

Volumn 73, Issue 8, 2014, Pages 770-779

  Tatenhorst, Lars ^a   Tönges, Lars ^a   Saal, Kim Ann ^a   Koch, Jan C ^a   Szego, Éva M ^b   Bähr, Mathias ^a,c   Lingor, Paul ^a,c  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain   (Germany)

Author keywords

6 OHDA; Axonal degeneration; Dopaminergic cell death; Parkinson disease; Regeneration; Rho kinase

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; DRINKING WATER; FASUDIL; OXIDOPAMINE; RHO KINASE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL COMPOSITION; BRAIN CORTEX LESION; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOSE TIME EFFECT RELATION; ENZYME INHIBITION; EXPERIMENTAL PARKINSONISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NERVE FIBER REGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TREATMENT RESPONSE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADRENERGIC AGENTS; ANIMALS; APOMORPHINE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MUSCLE STRENGTH; OXIDOPAMINE; PARKINSON DISEASE; PROTEIN KINASE INHIBITORS; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84904717584     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000095     Document Type: Article

References (33)

1. Burke RE, OMalley K. Axon degeneration in Parkinsons disease. Exp Neurol 2013;246:72-83
2. Fearnley JM, Lees AJ. Ageing and Parkinsons disease: Substantia nigra regional selectivity. Brain 1991;114:2283-301
3. De la Fuente-Fernández R, Schulzer M, Kuramoto L, et al. Age-specific progression of nigrostriatal dysfunction in Parkinsons disease. Ann Neurol 2011;69:803-10
4. Deumens R, Blokland A, Prickaerts J. Modeling Parkinsons disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002;175:303-17
5. Schober A. Classic toxin-induced animal models of Parkinsons disease: 6-OHDA and MPTP. Cell Tissue Res 2004;318:215-24
6. Finkelstein DI, Stanic D, Parish CL, et al. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 2000;97:99-112
7. Lees AJ, Hardy J, Revesz T. Parkinsons disease. Lancet 2009;373: 2055-66
8. Tönges L, Koch J-C, Bähr M, et al. ROCKing regeneration: Rho kinase inhibition as molecular target for neurorestoration. Front Mol Neurosci 2011;4:39
9. Lingor P, Teusch N, Schwarz K, et al. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J Neurochem 2007;103:181-89
10. Tönges L, Frank T, Tatenhorst L, et al. Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinsons disease. Brain 2012;135:3355-70
11. Maekawa M, Ishizaki T, Boku S, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999;285:895-98
12. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005;4:387-98
13. Alvarez-Fischer D, Henze C, Strenzke C, et al. Characterization of the striatal 6-OHDA model of Parkinsons disease in wild type and alphasynucleinYdeleted mice. Exp Neurol 2008;210:182-93
14. Tönges L, Günther R, Suhr M, et al. Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia 2014;62:217-32
15. Schallert T, Fleming SM, Leasure JL, et al. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000;39:777-87
16. Dehmer T, Heneka MT, Sastre M, et al. Protection by pioglitazone in the MPTP model of Parkinsons disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004;88:494-501
17. Lee J, Zhu W-M, Stanic D, et al. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain 2008;131:1574-87
18. DučićT, Barski E, Salome M, et al. X-ray fluorescence analysis of iron and manganese distribution in primary dopaminergic neurons. J Neurochem 2013;124:250-61
19. Zar JH. Biostatistical Analysis. 4th ed. Upper Saddle River, NJ: Prentice Hall, 1999
20. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 1971;367:69-93
21. Ishida T, Takanashi Y, Kiwada H. Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil. Biol Pharm Bull 2006;29:397-402
22. Suzuki Y, Shibuya M, Satoh S-I, et al. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol 2007;68:126-32
23. Orimo S, Uchihara T, Nakamura A, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinsons disease. Brain 2008;131:642-50
24. Blandini F, Armentero M-T. Animal models of Parkinsons disease. FEBS J 2012;279:1156-66
25. Stott SRW, Barker RA. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinsons disease. Eur J Neurosci 2014;39:1042-56
26. Bové J, Perier C. Neurotoxin-based models of Parkinsons disease. Neuroscience 2012;211:51-76
27. Zetterström T, Sharp T, Ungerstedt U. Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur J Pharmacol 1984;106:27-37
28. Iancu R, Mohapel P, Brundin P, et al. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinsons disease in mice. Behav Brain Res 2005;162:1-10
29. Lingor P, Tönges L, Pieper N, et al. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain 2008;131:250-63
30. Guo R, Liu B, Zhou S, et al. The protective effect of fasudil on the structure and function of cardiac mitochondria from rats with type 2 diabetes induced by streptozotocin with a high-fat diet is mediated by the attenuation of oxidative stress. Biomed Res Int 2013;2013: 430791
31. Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: A double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005;46:1803-11
32. Stocchi F, Olanow CW. Obstacles to the development of a neuroprotective therapy for Parkinsons disease. Mov Disord 2013;28:3-7
33. Love S, Plaha P, Patel NK, et al. Glial cell lineYderived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 2005;11:703-4